Cure My Disease

Don't miss your cure!

 Log in / Sign up

Leftover blood samples could unlock new medical discoveries

NCT ID NCT04364503

Knowledge-focused Sponsor: Sequenom, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study collects leftover blood or tissue samples and related health data from people who have already had lab tests at LabCorp. The goal is to build a large, de-identified resource that scientists can use for future research on pregnancy, cancer, and infectious diseases. Some participants may also be asked for additional samples or information if they give permission. No new treatments are being tested here—this is about gathering data to fuel future discoveries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2018

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Arm 1 - Female or male patient samples submitted to Sequenom or LabCorp affiliate for routine clinical care testing that no longer need to be maintained for clinical purposes. Arm 2 - Female or male subjects of scientific interest who have provided written informed consent/assent.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Arm 1 * All samples and data are de-identified and HIPAA compliant * Arm 2 * Subject is of scientific interest to the Sponsor or treating physician * Subject provides written informed consent and has a clinical sample and/or supporting clinical data collected. Exclusion Criteria: * Arm 1 * Subject is from a US state or a country where local law restricts the use of de-identified data and/or remnants of specimens for research and/or development * Arm 2 * Any medical or mental condition that would interfere with the subjects' ability to willingly give written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer infectious disease neoplasm pregnancy disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Infectious disease Pregnancy related

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Labcorp

    Los Angeles, California, 90064, United States

  • Labcorp

    Burlington, North Carolina, 27215, United States

  • Labcorp

    Research Triangle Park, North Carolina, 27709, United States

  • Labcorp - Cytogenetics

    Research Triangle Park, North Carolina, 27709, United States

  • Labcorp - Esoterix

    Englewood, Colorado, 80112, United States

  • Labcorp - Litholink

    Itasca, Illinois, 60143, United States

  • Labcorp - Monogram Biosciences

    South San Francisco, California, 94080, United States

  • Labcorp - Omniseq

    Buffalo, New York, 14203, United States

  • Sequenom, Inc

    San Diego, California, 92121, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.